Asuragen Licenses RNA, DNA Standards Technology to BD for MDx Development | GenomeWeb

NEW YORK (GenomeWeb News) – Asuragen today announced it has granted Becton Dickinson the rights to incorporate its Armored RNA technology into BD's in vitro molecular diagnostic products.

Asuragen will develop and supply reagents for BD Diagnostics in Asuragen's cGMP manufacturing facility under the terms of the deal. Other details of the non-exclusive worldwide agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.